Last reviewed · How we verify
Recombinant human tissue kallikrein
At a glance
| Generic name | Recombinant human tissue kallikrein |
|---|---|
| Also known as | DM199 |
| Sponsor | DiaMedica Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (PHASE2, PHASE3)
- Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema (PHASE3)
- Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke (PHASE2)
- An Open Label, Phase 1b, Ascending Dose Study of DM199 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant human tissue kallikrein CI brief — competitive landscape report
- Recombinant human tissue kallikrein updates RSS · CI watch RSS
- DiaMedica Therapeutics Inc portfolio CI